Sign In
Buy IMGN
$31.23
+0 (+0%)
At Close: May 08, 2024
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
11:01am, Friday, 02'nd Dec 2022 Benzinga
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Th
ImmunoGen: Elucidating Ramifications Of The Elahere Approval
03:15am, Thursday, 24'th Nov 2022
ImmunoGen recently gained the accelerated approval of mirvetuximab (Elahere) for resistant ovarian cancers with high FRA expression. As the first-of-its-kind, Elahere would enjoy strong market demands
Why Jim Cramer Sees 'Another Bad Quarter Ahead' For Ford, And What Will Turn Things Around
01:09pm, Wednesday, 23'rd Nov 2022 Benzinga
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vista Outdoor Inc (NYSE: VSTO) can be "bought here. I would not push it, though."
Benzinga's analyst ratings data shows a consensus Buy rating
After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst
07:21pm, Wednesday, 16'th Nov 2022 Benzinga
Tuesday, the FDA granted accelerated approval for ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) for folate receptor alpha (FRα)-positive, platinum-resistant epithelial o
Expert Ratings for Immunogen
03:03pm, Wednesday, 16'th Nov 2022 Benzinga
Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
3
0
0
0
Last
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
10:01am, Wednesday, 16'th Nov 2022 Benzinga
Gainers
Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday.
Tenax Therapeutics, Inc. (NASDAQ: TENX) jumped 45.7% to close at $0.1351 on Tuesday.
Exagen Inc.
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
05:56pm, Tuesday, 15'th Nov 2022 Zacks Investment Research
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
Vodafone, Getty Images Holdings, Haynes International And Some Other Big Stocks Moving Lower On Tuesday
04:17pm, Tuesday, 15'th Nov 2022 Benzinga
U.S. stocks traded higher, with the Nasdaq gaining more than 200 points on Tuesday. Here are some big stocks recording losses in today’s session.
AMMO, Inc. (NASDAQ: POWW) shares tumbled 26% to $2
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
02:18pm, Tuesday, 15'th Nov 2022
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday
12:26pm, Tuesday, 15'th Nov 2022 Benzinga
Chardan Capital raised PDS Biotechnology Corporation (NASDAQ: PDSB) price target from $15 to $16. . Chardan Capital analyst Geulah Livshits maintained the stock with a Buy rating. PDS Biotechnology
HUYA, Tencent Music Entertainment, Taiwan Semiconductor Manufacturing, And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
11:29am, Tuesday, 15'th Nov 2022 Benzinga
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Azenta, Inc. (NASDAQ: AZTA) shares jumped 35.7% to $63.27 in pre-marke
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
07:07pm, Monday, 07'th Nov 2022 Zacks Investment Research
ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
03:48pm, Monday, 07'th Nov 2022
ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates.
ImmunoGen, Inc. (IMGN) Q3 2022 Earnings Call Transcript
01:22pm, Friday, 04'th Nov 2022
ImmunoGen, Inc. (NASDAQ:IMGN ) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Company Participants Anabel Chan - Head, Investor Relations Mark Enyedy - President, CEO & Director Anna Ber
ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates
09:02am, Friday, 04'th Nov 2022
ImmunoGen (IMGN) delivered earnings and revenue surprises of -19.23% and 30.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
